The Clades of HIV: Their origins and clinical significance

AIDS Reviews

Volumn 5, Issue 4, 2003, Pages 205-213

  Stebbing, Justin ^a   Moyle, Graeme ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretrovirals; Clade; HIV; Subtype; Superinfection

Indexed keywords

ADEFOVIR; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; DIDANOSINE; ENFUVIRTIDE; LAMIVUDINE; LENTIVIRUS VECTOR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS VACCINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIOMEDICINE; CLADISTICS; CLINICAL TRIAL; DEATH; DRUG EFFICACY; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENTIVIRINAE; NONHUMAN; REVIEW; SUPERINFECTION; TREATMENT FAILURE; VIRUS GENE; VIRUS IDENTIFICATION; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; PEPTIDE FRAGMENTS; SUPERINFECTION; VARIATION (GENETICS);

EID: 1342329646     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Ho D, Huang Y. The HIV-1 vaccine race. Cell 2002;110:135-8.
2. De Cock K, Mbori-Ngacha D, Marum E. Shadow on the continent: Public health and HIV/AIDS in Africa in the 21st century. Lancet 2002;360:67-72.
3. Stebbing J, Patterson S, Gotch F. New insights into the immunology and evolution of HIV. Cell Res 2003;13:1-7.
4. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
5. Hammer M. Increasing choices for HIV therapy. N Engl J Med. 2002;346:2022-3.
6. Chun T, Fauci A. Latent reservoirs of HIV: Obstacles to the eradication of virus. Proc Natl Acad Sci USA 1999;96:10958-61.
7. Siliciano J, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4(+) T-cells. Nat Med 2003;9:727-8.
8. Stebbing J, Gazzard B. Clinical utility of resistance testing. Journal of HIV Therapy 2002;7:75-80.
9. Barreiro P, García-Benayas T, Soriano V, Gallant J. Simplification of antiretroviral treatment - How to sustain success, reduce toxicity and ensure adherence avoiding PI use. AIDS Rev 2002;4:233-41.
10. Gilbert S, Plebanski M, Gupta S, et al. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 1998;279:1173-7.
11. Holmes E. On the origin and evolution of the HIV. Biol Rev Camb Philos Soc 2001;76:239-54.
12. Stebbing J, Portsmouth S, Gazzard B. Virus-host interactions. Journal of the Royal College of Obstetricians and Gynaecologists 2002;9:152-9.
13. Muñoz J, Parks W, Wolinsky S, Korber B, Hutto C. HIV-1 reverse transcriptase. A diversity generator and quasispecies regulator. Ann N Y Acad Sci 1993;693:65-70.
14. Moyle G. Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: The potential to use resistance data to guide clinical decisions. J Antimicrob Chemother 1997;40:765-77.
15. Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
16. Gerrish P. The rhythm of microbial adaptation. Nature 2001;413:299-302.
17. Zhu T, Korber B, Nahmias A, Hooper E, Sharp P, Ho D. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature 1998;391:594-7.
18. Korber B, Muldoon M, Theiler J, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000;288:1789-96.
19. Gao F, Bailes E, Robertson D, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999;397:436-41.
20. Hahn B, Shaw G, De Cock K, Sharp P. AIDS as a zoonosis: Scientific and public health implications. Science 2000;287:607-14.
21. Goldman N, Anderson J, Rodrigo A. Likelihood-based tests of topologies in phylogenetics. Syst Biol 2000;49:652-70.
22. Lemey P, Pybus O, Wang B, Saksena N, Salemi M, Vandamme A. Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci USA 2003;100:6588-92.
23. De Groot N, Otting N, Doxiadis G, et al. Evidence for an ancient selective sweep in the MHC class I gene repertoire of chimpanzees. Proc Natl Acad Sci USA 2002;99:11748-53.
24. Perrin L, Kaiser L, Yerly S. Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis 2003;3:22-7.
25. Robertson D, Anderson J, Bradac J, et al. HIV-1 nomenclature proposal. Science. 2000;288:55-6.
26. Thomson M, Delgado E, Manjon N, et al. HIV-1 genetic diversity in Galicia Spain: BG intersubtype recombinant viruses circulating among injecting drug users. AIDS 2001;15:509-16.
27. Delgado E, Thomson M, Villahermosa M, et al. Identification of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Galicia, Spain, which exhibits a pseudotype-like virion structure. J Acquir Immune Defic Syndr 2002;29:536-43.
28. Rinke De Wit T, Tsegaye A, Wolday D, et al. Primary HIV-1 subtype C infection in Ethiopia. J Acquir Immune Defic Syndr 2002;30:463-70.
29. Esteves A, Parreira R, Venenno T, et al. Molecular epidemiology of HIV type 1 infection in Portugal: High prevalence of non-B subtypes. AIDS Res Hum Retroviruses 2002;18:313-25.
30. Zewde A, Bahiru S, Sanders E, et al. HIV-1 seroprevalence and subtypes in police recruits from Afar regional state, Ethiopia. Ethiop Med J 2002;40(Suppl 1):1-10.
31. Yang R, Xia X, Kusagawa S, Zhang C, Ben K, Takebe Y. Ongoing generation of multiple forms of HIV-1 intersubtype recombinants in the Yunnan Province of China. AIDS 2002;16:1401-7.
32. Sánchez-Merino V, Herrero C, Amorin-Nink A, Von Briesen H, López-Galíndez C. Genetic analysis of culture-negative UNAIDS subtype C samples. AIDS Res Hum Retroviruses 2003;19:49-55.
33. Kuiken C, Foley B, Hahn B, Korber B, McCutchan F, Marx P. Human Retroviruses and AIDS 1999: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos, NM 1999.
34. Swanson P, Devare S, Hackett J. Full-length sequence analysis of HIV-1 isolate CM237: A CRF01_AE/B intersubtype recombinant from Thailand. AIDS Res Hum Retroviruses 2003;19:707-12.
35. Ramos A, Nguyen L, Hu D, et al. New HIV type 1 CRF01_AE/B recombinants displaying unique distribution of breakpoints from incident infections among injecting drug users in Thailand. AIDS Res Hum Retroviruses 2003;19:667-74.
36. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002;29:184-90.
37. Vidal N, Peeters M, Mulanga-Kabeya C, et al. Unprecedented degree of HIV-1 group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. J Virol 2000;74:10498-507.
38. Smith U, Kuiken C, Korber B. Recent evolutionary history of HIV type 1 subtype B-response. J Mol Evol 2003;56:643-4.
39. Robbins K, Lemey P, Pybus O, et al. U.S. HIV type 1 epidemic: Date of origin, population history, and characterization of early strains. J Virol 2003;77:6359-66.
40. Kuiken C, Thakallapalli R, Esklid A, De Ronde A. Genetic analysis reveals epidemiologic patterns in the spread of HIV. Am J Epidemiol 2000;152:814-22.
41. Bobkov A, Cheingsong-Popov R, Selimova L, et al. An HIV type 1 epidemic among injecting drug users in the former Soviet Union caused by a homogeneous subtype A strain. AIDS Res Hum Retroviruses 1997;13:1195-201.
42. Kalish M, Baldwin A, Raktham S, et al. The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: Implications for HIV vaccine trials. AIDS 1995;9:851-7.
43. Magiorkinis G, Paraskevis D, Magiorkinis E, Vandamme A, Hatzakis A. Reanalysis of the HIV-1 circulating recombinant form A/E (CFR01_AE): Evidence of A/E/G recombination. J Acquir Immune Defic Syndr 2002;30:124-9.
44. Subbarao S, Vanichseni S, Hu D, et al. Genetic characterization of incident HIV type 1 subtype E and B strains from a prospective cohort of injecting drug users in Bangkok, Thailand. AIDS Res Hum Retroviruses 2000;16:699-707.
45. Triques K, Bourgeois A, Saragosti S, et al. High diversity of HIV-1 subtype F strains in Central Africa. Virology 1999; 259:99-109.
46. Lukashov V, Cornelissen M, Goudsmit J, et al. Simultaneous introduction of distinct HIV-1 subtypes into different risk groups in Russia, Byelorussia and Lithuania. AIDS 1995;9:435-9.
47. Duque V, Holguín A, Silvestre M, González-Lahoz J, Soriano V. HIV type 1 recombinant B/G subtypes circulating in Coimbra, Portugal. Clin Microbiol Infect 2003;9:422-5.
48. Auerbach D, Darrow W, Jaffe H, Curran J. Cluster of cases of the acquired immune deficiency syndrome. Patients linked by sexual contact. Am J Med 1984;76:487-92.
49. Hoelscher M, Kim B, Maboko L, et al. High proportion of unrelated HIV-1 intersubtype recombinants in the Mbeya region of southwest Tanzania. AIDS 2001;15:1461-70.
50. Thomson M, Delgado E, Herrero I, et al. Diversity of mosaic structures and common ancestry of HIV type 1 BF intersubtype recombinant viruses from Argentina revealed by analysis of near full-length genome sequences. J Gen Virol 2002; 83:107-19.
51. Thomson M, Villahermosa M, Vázquez-de-Parga E, et al. Widespread circulation of a B/F intersubtype recombinant form among HIV-1-infected individuals in Buenos Aires, Argentina. AIDS 2001;14:897-9.
52. Altfeld M, Allen T, Yu X, et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002;420:434-9.
53. Valer L, De Mendoza C, Soriano V. HIV superinfection: Clinical and biological implications. Med Clin (Barc) 2003;121:192-6.
54. Rosenberg E, Altfeld M, Poon S, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-6.
55. Long E, Martin H, Kreiss J, et al. Gender differences in HIV-1 diversity at time of infection. Nat Med 2000;6:71-5.
56. Stebbing J, Portsmouth S. AIDS vaccine research. HIV and AIDS Current Trends 2002;8:15-7.
57. Schmitz J, Kuroda M, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-60.
58. Walker B, Korber B. Immune control of HIV: The obstacles of HLA and viral diversity. Nat Immunol 2001;2:473-5.
59. Migueles S, Laborico A, Shupert W, et al. HIV-specific CD8(+) T-cell proliferation is coupled to perforin expression and is maintained in non-progressors. Nat Immunol 2002;3:1061-8.
60. Stebbing J, Gazzard B, Kim L, et al. The heat shock protein receptor CD91 is upregulated in monocytes of HIV-1-infected 'true' long-term non-progressors. Blood 2003;16:16.
61. Rowland-Jones S, Pinheiro S, Kaul R. New insights into host factors in HIV-1 pathogenesis. Cell 2001;104:473-6.
62. Goulder P, Brander C, Tang Y, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001;412:334-8.
63. Harrigan P, Montaner J, Wegner S, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: Biologically relevant values for resistance testing. AIDS 2001; 15:1671-7.
64. Frater J. The impact of HIV-1 subtype on the clinical response on HAART. J HIV Ther 2002;7:92-6.
65. Larder B, Kemp S. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-8.
66. Patel P, Preston B. Marked infidelity of HIV type 1 reverse transcriptase at RNA and DNA template ends. Proc Natl Acad Sci USA 1994;91:549-53.
67. Schliekelman P, Garner C, Slatkin M. Natural selection and resistance to HIV. Nature 2001;411:545-6.
68. Svedhem V, Lindvist A, Lidman K, Sonnerborg A. Persistence of earlier HIV-1 drug-resistance mutations at new treatment failure. J Med Virol 2002;68:473-8.
69. Mansky L, Pearl D, Gajary L. Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of HIV type 1 mutant frequencies. J Virol 2002;76:9253-9.
70. Suchard M, Weiss R, Sinsheimer J. Bayesian selection of continuous-time Markov chain evolutionary models. Mol Biol Evol 2001;18:1001-13.
71. Donnelly C, Cox D. Mathematical biology and medical statistics: Contributions to the understanding of AIDS epidemiology. Stat Methods Med Res 2001;10:141-54.
72. Luk K, Kaptue L, Zekeng L, et al. Naturally occurring sequence polymorphisms within HIV type 1 group O protease. AIDS Res Hum Retroviruses 2001;17:1555-61.
73. Pieniazek D, Rayfield M, Hu D, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 2000;14:1489-95.
74. Handema R, Terunuma H, Kasolo F, et al. Prevalence of drug resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Res Hum Retroviruses 2003;19:151-60.
75. Perno C, Cozzi-Lepri A, Balotta C, et al. Impact of mutations conferring reduced susceptibility to lamivudine on the response to antiretroviral therapy. Antivir Ther 2001;6:195-8.
76. Perno C, Cozzi-Lepri A, Balotta C, et al. Secondary mutations in the protease region of HIV and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001;184:983-91.
77. Palmer S, Alaeus A, Albert J, Cox S. Drug susceptibility of subtypes A, B, C, D, and E HIV type 1 primary isolates. AIDS Res Hum Retroviruses 1998;14:157-62.
78. Shafer R, Eisen J, Merigan T, Katzenstein D. Sequence and drug susceptibility of subtype C reverse transcriptase from HIV type 1 seroconverters in Zimbabwe. J Virol 1997;71:5441-8.
79. Caride E, Brindeiro R, Hertogs K, et al. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of HIV type I found in Brazilian patients failing HAART. Virology 2000;275:107-15.
80. Palmer S, Margot N, Gilbert H, Shaw N, Buckheit R, Miller M. Tenofovir, adefovir, and zidovudine susceptibilities of primary HIV type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses 2001;17:1167-73.
81. Easterbrook P, Smith M, Mullen J, Murad S, Kulasegaram B. Relationship Between HIV-1 Viral Subtype, Disease Progression and Response to Antiretroviral Therapy. British HIV Association. Manchester 2003.
82. Frater A, Beardall A, Ariyoshi K, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001;15:1493-502.
83. Alexander C, Montessori V, Wynhoven B, et al. Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir Ther 2002;7:31-5.
84. Cingolani A, Antinori A, Rizzo M, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 2002;16:369-79.
85. Turner B. Adherence to antiretroviral therapy by HIV-infected patients. J Infect Dis 2002;185(Suppl 2):143-51.
86. Gallant J. Initial therapy of HIV infection. J Clin Virol 2002;25:317-33.
87. Nieuwkerk P, Sprangers M, Burger D, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001;161:1962-8.
88. Walsh J, Pozniak A, Nelson M, Mandalia S, Gazzard B. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr 2002; 30:278-87.
89. Moore C, John M, James I, Christiansen F, Witt C, Mallal S. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002;296:1439-43.
90. Caride E, Hertogs K, Larder B, et al. Genotypic and phenotypic evidence of different drug resistance mutation patterns between B and non-B subtype isolates of HIV type 1 found in Brazilian patients failing HAART. Virus Genes 2001;23:193-202.
91. Hogluín A, Hertogs K, Soriano V. Performance of drug resistance assays in testing HIV-1 non-B subtypes. Clin Microbiol Infect 2003;9:323-6.
92. Gordon M, De Oliveira T, Bishop K, et al. Molecular characteristics of HIV type 1 subtype C viruses from KwaZulu-Natal, South Africa: Implications for vaccine and antiretroviral control strategies. J Virol 2003;77:2587-99.
93. Loemba H, Brenner B, Parniak M, et al. Genetic divergence of HIV type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against non-nucleoside inhibitors of RT. Antimicrob Agents Chemother 2002;46:2087-94.
94. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003;17:1-5.
95. Gallego O, Ruiz L, Vallejo A, Clotet B, Leal M, Soriano V. Rate of virological treatment failure and frequencies of drug resistance genotypes among HIV-positive subjects on antiretroviral therapy in Spain. J Clin Microbiol 2002;40:3865-6.
96. Lalezari J, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85.
97. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95.
98. Villahermosa M, Pérez-Álvarez L, Carmona R, et al. Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants. AIDS 2003;17:1083-6.
99. Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, Sugiura W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr 2003;33:336-42.
100. Renjifo B, Fawzi W, Mwkagile D, et al. Differences in perinatal transmission among HIV type 1 genotypes. J Hum Virol 2001;4:16-25.
101. Blackard J, Renjifo B, Mwkagile D, et al. Transmission of HIV type 1 viruses with intersubtype recombinant long terminal repeat sequences. Virology 1999;254:220-5.
102. Blackard J, Renjifo B, Chaplin B, Msamanga G, Fawzi W, Essex M. Diversity of the HIV-1 long terminal repeat following mother-to-child transmission. Virology 2000;274:402-11.
103. Beddows S, Galpin S, Kazmi S, et al. Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes. J Med Virol 2003;70:337-42.